Nanobiotix, a clinical-stage biotech company, announced a global share offering aiming to raise about €75 million ($87 million). The offering includes American Depositary Shares in the U.S. and ordinary shares plus pre-funded warrants in Europe and other countries. Proceeds will support development of cancer therapies, including JNJ-1900 and Nanoprimer platforms, and general corporate needs. The offering is subject to market conditions, with final pricing and share numbers to be announced post-bookbuilding.
High Arctic Overseas Holding Corp. has been appointed as the authorised sole distributor of Atlas Copco Power Technique products in Papua New Guinea. This partnership aims to introduce high-quality power generation, energy storage, mobile lighting, a...
Charlie's Holdings, a leader in premium vapor products, reported a 204% revenue increase to $4.8 million in Q1 2026 compared to Q1 2025, driven by strong sales of its SBX non-nicotine disposable vape line and new licensing for AI-powered age-gated pr...
Nanobiotix, a late-stage biotech company, announced a global follow-on offering aiming to raise approximately €75 million ($87 million). The offering includes American Depositary Shares in the U.S. and Ordinary Shares plus pre-funded warrants in Euro...
Capital City Bank Group, Inc. announced a quarterly cash dividend of $0.27 per share, translating to an annualized dividend of $1.08 per share. This dividend will be paid on June 15, 2026, to shareholders recorded as of June 1, 2026. The dividend yie...
Victoria’s Secret & Co. released an investor presentation showcasing its significant operational improvements and financial momentum under CEO Hillary Super and the Path to Potential strategy since 2021. The company emphasized its refreshed leadershi...
